| Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy AJ Rodger, V Cambiano, T Bruun, P Vernazza, S Collins, J Van Lunzen, ... Jama 316 (2), 171-181, 2016 | 1760 | 2016 |
| Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised … JL Lennox, E DeJesus, A Lazzarin, RB Pollard, JVR Madruga, DS Berger, ... The Lancet 374 (9692), 796-806, 2009 | 740 | 2009 |
| Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy DG Warr, PJ Hesketh, RJ Gralla, HB Muss, J Herrstedt, PD Eisenberg, ... Journal of Clinical Oncology 23 (12), 2822-2830, 2005 | 570 | 2005 |
| Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2 … JJ Eron, B Young, DA Cooper, M Youle, E DeJesus, ... The Lancet 375 (9712), 396-407, 2010 | 363 | 2010 |
| Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1–infected patients: final 5-year results from … JK Rockstroh, E DeJesus, JL Lennox, Y Yazdanpanah, MS Saag, H Wan, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 63 (1), 77-85, 2013 | 304 | 2013 |
| Raltegravir versus efavirenz regimens in treatment-naive HIV-1–infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses JL Lennox, E DeJesus, DS Berger, A Lazzarin, RB Pollard, JVR Madruga, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 55 (1), 39-48, 2010 | 297 | 2010 |
| Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial JJ Eron, JK Rockstroh, J Reynes, J Andrade-Villanueva, ... The Lancet infectious diseases 11 (12), 907-915, 2011 | 226 | 2011 |
| Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority … JM Molina, K Squires, PE Sax, P Cahn, J Lombaard, E DeJesus, MT Lai, ... The lancet HIV 5 (5), e211-e220, 2018 | 221 | 2018 |
| Long-term Treatment With Raltegravir or Efavirenz Combined With Tenofovir/Emtricitabine for Treatment-Naive Human Immunodeficiency Virus-1–Infected Patients … JK Rockstroh, JL Lennox, E DeJesus, MS Saag, A Lazzarin, H Wan, ... Clinical infectious diseases 53 (8), 807-816, 2011 | 211 | 2011 |
| Treatment of hospitalized patients with complicated Gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus … RL Nichols, DR Graham, SL Barriere, A Rodgers, SE Wilson, M Zervos, ... Journal of Antimicrobial Chemotherapy 44 (2), 263-273, 1999 | 203 | 1999 |
| Doravirine/lamivudine/tenofovir disoproxil fumarate is non-inferior to efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive adults with human … C Orkin, KE Squires, JM Molina, PE Sax, WW Wong, O Sussmann, ... Clinical Infectious Diseases 68 (4), 535-544, 2019 | 182 | 2019 |
| Efficacy and tolerability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss DA Whiting, EA Olsen, R Savin, L Halper, A Rodgers, W Lixia, C Hustad, ... European Journal of Dermatology 13 (2), 150-60, 2003 | 129 | 2003 |
| Efficacy and tolerability of aprepitant for the prevention of chemotherapy‐induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy J Herrstedt, HB Muss, DG Warr, PJ Hesketh, PD Eisenberg, ... Cancer 104 (7), 1548-1555, 2005 | 128 | 2005 |
| Applying a 3.0 transformation framework to guide large-scale health system reform N Halfon, P Long, DI Chang, J Hester, M Inkelas, A Rodgers Health Affairs 33 (11), 2003-2011, 2014 | 123 | 2014 |
| Efficacy of rizatriptan 10 mg administered early in a migraine attack R Cady, V Martin, A Mauskop, A Rodgers, CM Hustad, KE Ramsey, ... Headache: The Journal of Head and Face Pain 46 (6), 914-924, 2006 | 86 | 2006 |
| Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis TW Ho, A Rodgers, ME Bigal Headache: The Journal of Head and Face Pain 49 (3), 395-403, 2009 | 73 | 2009 |
| Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616 CM Ballantyne, P Banka, G Mendez, R Garcia, J Rosenstock, A Rodgers, ... Journal of the American College of Cardiology 81 (16), 1553-1564, 2023 | 71 | 2023 |
| Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: two prospective, randomized, placebo-controlled, double-blind studies LK Mannix, E Loder, R Nett, L Mueller, A Rodgers, CM Hustad, ... Cephalalgia 27 (5), 414-421, 2007 | 66 | 2007 |
| Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1–infected patients: Week-192 overall and subgroup analyses from STARTMRK E DeJesus, JK Rockstroh, JL Lennox, MS Saag, A Lazzarin, J Zhao, ... HIV clinical trials 13 (4), 228-232, 2012 | 62 | 2012 |
| Symptoms of cutaneous sensitivity pre-treatment and post-treatment: results from the rizatriptan TAME studies R Cady, V Martin, A Mauskop, A Rodgers, CM Hustad, KE Ramsey, ... Cephalalgia 27 (9), 1055-1060, 2007 | 54 | 2007 |
